ReviewInflammopharmacology2012
The role of inflammatory processes in Alzheimer's disease.
Review in Inflammopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 68 citations in OpenAlex.
- ApoE4 Upregulates GSK-3β to Aggravate Alzheimer-Like Pathologies and Cognitive Impairment in Type 2 Diabetic Mice.CNS neuroscience & therapeutics · 2025Article
- Targeting aging and age-related diseases with vaccines.Nature aging · 2024Review
- White matter hyperintensities in cholinergic pathways are associated with dementia severity in e4 carriers but not in non-carriers.Frontiers in neurology · 2023Article
- Implication of Adult Hippocampal Neurogenesis in Alzheimer's Disease and Potential Therapeutic Approaches.Cells · 2022Review
- The informed road map to prevention of Alzheimer Disease: A call to arms.Molecular neurodegeneration · 2021Review
- Dietary Protein Source Influences Brain Inflammation and Memory in a Male Senescence-Accelerated Mouse Model of Dementia.Molecular neurobiology · 2021Article
- From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer's Disease.Current neuropharmacology · 2021Review
- The effect of insomnia on development of Alzheimer's disease.Journal of neuroinflammation · 2020Review
- Shared genetic etiology underlying late-onset Alzheimer's disease and posttraumatic stress syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Article
- Nrf2 Ablation Promotes Alzheimer's Disease-Like Pathology in APP/PS1 Transgenic Mice: The Role of Neuroinflammation and Oxidative Stress.Oxidative medicine and cellular longevity · 2020Article
- Article
- Analysis of pleiotropic genetic effects on cognitive impairment, systemic inflammation, and plasma lipids in the Health and Retirement Study.Neurobiology of aging · 2019Article
- Burn-Induced Microglia Activation is Associated With Motor Neuron Degeneration and Muscle Wasting in Mice.Shock (Augusta, Ga.) · 2019Article
- A Review and Hypothesized Model of the Mechanisms That Underpin the Relationship Between Inflammation and Cognition in the Elderly.Frontiers in aging neuroscience · 2019Article
- Neuroprotective Effect of Caffeic Acid Phenethyl Ester in A Mouse Model of Alzheimer's Disease Involves Nrf2/HO-1 Pathway.Aging and disease · 2018Article
- Use of curcumin in diagnosis, prevention, and treatment of Alzheimer's disease.Neural regeneration research · 2018Review
- Peripheral complement interactions with amyloid β peptide: Erythrocyte clearance mechanisms.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017Article
- Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease.Redox biology · 2017Article
- Apolipoprotein E as a Therapeutic Target in Alzheimer's Disease: A Review of Basic Research and Clinical Evidence.CNS drugs · 2016Review
- Increased CSF levels of aromatic amino acids in hip fracture patients with delirium suggests higher monoaminergic activity.BMC geriatrics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has become increasingly clear that inflammatory processes play a significant role in the pathophysiology of Alzheimer's disease (AD). Neuroinflammation is characterized by the activation of astrocytes and microglia and the release of proinflammatory cytokines and chemokines. Vascular inflammation, mediated largely by the products of endothelial activation, is accompanied by the production and the release of a host of inflammatory factors which contribute to vascular, immune, and neuronal dysfunction. The complex interaction of these processes is still only imperfectly understood, yet as the mechanisms continue to be elucidated, targets for intervention are revealed. Although many of the studies to date on therapeutic or preventative strategies for AD have been narrowly focused on single target therapies, there is accumulating evidence to suggest that the most successful treatment strategy will likely incorporate a sequential, multifactorial approach, addressing direct neuronal support, general cardiovascular health, and interruption of deleterious inflammatory pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.